Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Harbor Therapeutics
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patient is male and at least 18 years of age, at the time of screening;
Patient has metastatic disease (any T, any N, M1);
Patient has failed at least 1 taxane regimen; or Patient has symptomatic or asymptomatic CRPC and is chemotherapy-naïve
Patient has histologically or cytologically confirmed adenocarcinoma of the prostate;
Patient has progression of disease despite adequate hormone therapy, demonstrated by one of the following:
* PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions, at least 1 week apart.
* Evaluable disease progression by modified RECIST (Response Evaluation Criteria in Solid Tumors) criteria;
* Progression of metastatic bone disease on bone scan with \> 2 new lesions
Patient has ECOG (Eastern Cooperative Oncology Group) performance status of 0-2;
You may not be if
Patient has symptomatic parenchymal brain metastases or active epidural disease requiring whole-brain irradiation Treated epidural disease is allowed
Patient has active infection;
Patient having a history of clinically significant cardiovascular disease (such as CHF), clinically significant hepatic, respiratory or renal abnormalities;
Patient who has any clinically significant abnormalities in laboratory results at screening
Patient who has a history of clinically significant neurological or psychiatric condition;
Additional criteria are applicable to expansion cohorts.
Clareo Health | A Phase I/II Study of HE3235 in Patients With Prostate Cancer
